A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Filgrastim; Pegfilgrastim
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 24 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 28 Jun 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 05 Jun 2018 Results (n=38) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.